EQT offers EUR 46.50 per share in Qiagen stock takeover

Published on 10/26/2026 at 11:23 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

EQT proposed EUR 46.50 per Qiagen share in a takeover. Qiagen stock was at EUR 45.02 on October 26, 2026.

Transaction and operating markers

EQT proposed a EUR 46.50-per-share takeover of Qiagen on October 22, 2026.
Preliminary third-quarter net sales reached USD 548 million on October 21, 2026.
Qiagen stock was trading at EUR 45.02 at 11:17 a.m. CEST at Lang & Schwarz on October 26, 2026.

Pipette tropft klare Flüssigkeit in sterile 96-Well-Platte, klinisches Laborlicht — Qiagen N.V. (NL0012169213) Pipette tropft klare Flüssigkeit in sterile 96-Well-Platte im klinischen Labor, Illustration mit AI erstellt.

Qiagen (ISIN NL0015002SN0) and EQT Private Equity announced a proposed all-cash takeover at EUR 46.50 per share on October 22, 2026. The offer values Qiagen at about EUR 10.8 billion in enterprise value, according to BioSpectrum Asia.

Takeover offer sets the price

The proposed offer covers all outstanding shares and requires a minimum acceptance threshold of 50 percent plus one share. Completion is expected in mid-2027, subject to regulatory clearances and other conditions described in the offer document.

The offer price is also the central reference for the stock because the transaction is designed to deliver cash value while Qiagen continues operating independently until completion. The company said its boards approved the agreement and intend to recommend that shareholders tender their shares.

What does the offer mean for results?

Qiagen reported preliminary third-quarter 2026 net sales of USD 548 million and adjusted diluted earnings per share of USD 0.65. The figures were reported at both actual and constant exchange rates in the Business Wire release dated October 21, 2026.

Qiagen suspended its full-year 2026 outlook while the transaction remains pending. That changes the investor discussion from standalone earnings visibility toward offer conditions, shareholder approval and the timing of regulatory decisions.

Three dated developments

On October 21, 2026, Qiagen announced preliminary third-quarter sales of USD 548 million and adjusted diluted earnings per share of USD 0.65. On October 22, 2026, EQT proposed EUR 46.50 per share in cash for the company. On October 23, 2026, Baird reduced its rating from Outperform to Neutral while keeping a USD 52.00 price target, as reported by MarketBeat.

Next dates for Qiagen

Qiagen plans to publish full third-quarter 2026 results on November 4, 2026, at 10:05 p.m. Frankfurt time, according to Business Wire. The proposed takeover is expected to close in mid-2027, subject to its conditions, as reported by BioSpectrum Asia.

Stock price and transaction gap

Qiagen was trading at EUR 45.02 at Lang & Schwarz on October 26, 2026 at 11:17 a.m. CEST. The current euro quotation is below the proposed EUR 46.50 cash offer, leaving the transaction terms as the key market reference while approval steps continue. The further course of trading is shown by the continuously updated real-time quote of Qiagen stock.